Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $389.27 USD
Change Today -12.44 / -3.10%
Volume 3.4M
BIIB On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 8:10 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

225 Binney Street

Cambridge, MA 02142

United States

Phone: 617-679-2000

Fax:

RIDY. Additional protection for PLEGRIDY is provided by patents and patent applications with expiration dates out to 2025 in the U.S. and 2019 in the E.U., with the potential for patent term extension. PLEGRIDY is also entitled to regulatory exclusivity until 2026 in the U.S. and 2024 in the E.U. TECFIDERA The company has the U.S. patents and patent applications, and various corresponding foreign counterparts, related to TECFIDERA. Its principal the U.S. patents and expiration dates, subject to pending applications for patent term extension, are U.S. patent no. 6,509,376, having claims to formulations of dimethyl fumarate for use in the treatment of autoimmune diseases, including MS, expiring in 2019; U.S. patent no. 7,320,999, having claims to a method of treating MS using dimethyl fumarate, expiring in 2020; U.S. patent no. 7,619,001, having claims to a method of treating MS using dimethyl fumarate, monomethyl fumarate, or a combination thereof, expiring in 2018; U.S. patent no. 7,803,840, having claims to a method of treating an autoimmune disease selected from autoimmune polyarthritis and MS using dimethyl fumarate, expiring in 2018; U.S. patent no. 8,399,514, covering the dosing regimen of 480 mg per day of dimethyl fumarate, monomethyl fumarate or combinations thereof for treating MS, expiring in 2028; U.S. patent no. 8,524,773, having claims to a method of treating MS using dimethyl fumarate, expiring in 2018; and U.S. patent no. 8,759,393, having claims to formulations of dimethyl fumarate, expiring in 2019. The company’s principal European patents and expiration dates, subject to pending applications for supplemental patent certificates, are European patent no. (EP) 1131065, directed to formulations of dimethyl fumarate and to uses thereof for treating autoimmune diseases, including MS, expiring in 2019; and EP 2137537, the counterpart patent to its the U.S. patent covering the dosing regimen of 480 mg per day of dimethyl fumarate or monomethyl fumarate for treating MS, expiring in 2028. In addition to patent protection, in the U.S. TECFIDERA is entitled to regulatory exclusivity until 2018. In the E.U., TECFIDERA is entitled to regulatory exclusivity until 2024. TYSABRI The company has patents and patent applications covering TYSABRI in the U.S. and other countries. These patents and patent applications cover TYSABRI and related manufacturing methods, as well as various methods of treatment using the product. The principal patents covering the product and use of the product to treat MS are U.S. patent nos. 5,840,299 and 6,602,503 and EP 0804237, which expire between 2017 and 2020 (including supplementary protection certificates in many European countries). Additional the U.S. and E.U. patents and applications covering methods of treatment using the product expire in 2023. In addition to patent protection, TYSABRI is entitled to regulatory exclusivity until 2016 in both the U.S. and the E.U. FAMPYRA The company has an exclusive license under two European granted patents, various pending European patent applications and numerous corresponding non-U.S. counterpart applications related to FAMPYRA. EP 0484186B1 claims pharmaceutical formulations containing aminopyridines, including fampridine. This patent expired in November 2011 but is subject to pending and granted supplemental protection certificates, which where granted, would extend the patent term to 2016 on a country-by-country basis. EP 1732548B1, which claims sustained-release aminopyridine compositions for increasing walking speed in patients with MS, and EP 2377536B1, which claims sustained-release aminopyridine compositions for treating MS, expire in 2025 but are subject to pending and granted supplemental protection certificates which, where granted, would extend one of the patents’ term to 2026 on a country-by-country basis. In addition to these patent rights, FAMPYRA is covered by regulatory exclusivity in Europe until 2021. ELOCTATE and ALPROLIX The company has the U.S. patents and patent applications, and various corresponding foreign counterparts, related to ELOCTATE and ALPROLIX and their use. The principal paten

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIIB:US $389.27 USD -12.44

BIIB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $65.02 USD -1.05
Bristol-Myers Squibb Co $65.16 USD -0.64
Celgene Corp $114.72 USD -3.99
Medtronic PLC $76.21 USD -1.40
Novo Nordisk A/S kr394.00 DKK +3.70
View Industry Companies
 

Industry Analysis

BIIB

Industry Average

Valuation BIIB Industry Range
Price/Earnings 29.0x
Price/Sales 9.3x
Price/Book 8.1x
Price/Cash Flow 25.4x
TEV/Sales 9.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN INC, please visit www.biogenidec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.